Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
01 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-announces-us-fda-approval-for-atzumi-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-302443234.html
26 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura-302316089.html
30 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura-302292154.html
08 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-announce-publication-of-sts101-dihydroergotamine-nasal-powder-pivotal-phase-3-ascend-study-in-cns-drugs-302270104.html
19 Jan 2024
// PRESS RELEASE
15 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/15/2688854/0/en/Satsuma-Pharmaceuticals-and-SNBL-Announce-Three-Abstracts-on-STS101-for-the-Acute-Treatment-of-Migraine-to-be-Presented-at-the-American-Headache-Society-s-65th-Annual-Scientific-Me.html
ABOUT THIS PAGE